Back to results
US 2020/0368276 A1Published application
Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AssigneeAxial Biotherapeutics, Inc.
InventorsAnthony Stewart Campbell, David H. Donabedian
Life of this patent
Estimating the term…
Abstract
The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.
Claims2
(canceled)
A method of treating a subject having a behavioral symptom of a neurological disorder associated with autism spectrum disorder, comprising:
- administering to the subject a therapeutically effective amount of an activated carbon sequestrant composition which binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract;
- wherein the at least one intestinal metabolite is 4-ethylphenol and the behavioral symptom is clinical irritability;
- wherein the sequestrant composition comprises a multiplicity of biocompatible particles which are non-absorbable by the digestive tract of the subject;
- wherein the therapeutically effective amount is 35 mg to 35 g per day;
- and wherein the therapeutically effective amount alleviates the clinical irritability.
2 more elements
Dependencies are inferred from the claim text.